Search results

We are listening to your views on this Technology appraisal guidance. Comments close 26 May 2022.

Type

Technology appraisal guidance

Status

In consultation

We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.

Type

Technology appraisal guidance

Status

In consultation

We are listening to your views on this Technology appraisal guidance. Comments close 13 June 2022.

Type

Technology appraisal guidance

Status

In consultation

We are listening to your views on this Technology appraisal guidance. Comments close 6 June 2022.

Type

Technology appraisal guidance

Status

In consultation

Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged

Type

Highly specialised technologies guidance

Published

20 July 2016

Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

Type

Highly specialised technologies guidance

Published

05 May 2022

Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults

Type

Highly specialised technologies guidance

Published

21 October 2020

Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults

Type

Highly specialised technologies guidance

Published

24 February 2021

Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children

Type

Highly specialised technologies guidance

Published

28 January 2015

Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating spinal muscular atrophy in babies

Type

Highly specialised technologies guidance

Published

07 July 2021

Evidence-based recommendations on givosiran (Givlaari) for treating acute hepatic porphyria in adults and young people aged 12 and over

Type

Highly specialised technologies guidance

Published

24 November 2021

Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages

Type

Highly specialised technologies guidance

Published

20 April 2022

Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Type

Highly specialised technologies guidance

Published

22 May 2019

Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

Type

Highly specialised technologies guidance

Published

10 October 2018

Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency

Type

Highly specialised technologies guidance

Published

07 February 2018

Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children

Type

Highly specialised technologies guidance

Published

02 August 2017

Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults

Type

Highly specialised technologies guidance

Published

28 June 2017

Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

Type

Highly specialised technologies guidance

Published

27 November 2019

Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

Type

Highly specialised technologies guidance

Published

09 October 2019

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Type

Highly specialised technologies guidance

Published

14 August 2019

Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older

Type

Highly specialised technologies guidance

Published

22 February 2022

Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children

Type

Highly specialised technologies guidance

Published

28 March 2022

Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16

Type

Highly specialised technologies guidance

Published

22 February 2017

Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion

Type

Technology appraisal guidance

Published

22 May 2013

NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks

Type

Technology appraisal guidance

Published

24 April 2013

Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures

Type

Technology appraisal guidance

Published

24 April 2013

Evidence-based recommendations on colistimethate sodium and tobramycin dry powders for inhalation for pseudomonas lung infection in cystic fibrosis

Type

Technology appraisal guidance

Published

27 March 2013

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation

Type

Technology appraisal guidance

Last updated

02 July 2021

Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema

Type

Technology appraisal guidance

Published

27 February 2013

Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered

Type

Technology appraisal guidance

Published

28 September 2016

NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals

Type

Technology appraisal guidance

Published

04 March 2020

Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults

Type

Technology appraisal guidance

Published

13 February 2020

Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2

Type

Technology appraisal guidance

Published

12 February 2020

Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Type

Technology appraisal guidance

Published

15 January 2020

Evidence-based recommendations on Palforzia for treating peanut allergy in children and young people

Type

Technology appraisal guidance

Published

02 February 2022

Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults

Type

Technology appraisal guidance

Published

02 February 2022

Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults

Type

Technology appraisal guidance

Published

24 January 2018

Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults

Type

Technology appraisal guidance

Published

12 July 2017

Evidence-based recommendations on darvadstrocel (Alofisel; stem-cell treatment) for complex perianal fistulas with mildly or non-active luminal Crohn’s disease

Type

Technology appraisal guidance

Published

09 January 2019

NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from

Type

Technology appraisal guidance

Published

13 March 2019

Evidence-based recommendations on autologous chondrocyte implantation (ACI) using chondrosphere (Spherox) for symptomatic articular knee cartilage defects

Type

Technology appraisal guidance

Published

07 March 2018

Evidence-based recommendations on lesinurad (Zurampic) for treating chronic hyperuricaemia (too much uric acid/urate in blood) in adults with gout

Type

Technology appraisal guidance

Published

07 February 2018

Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults

Type

Technology appraisal guidance

Published

15 November 2017

Evidence-based recommendations on autologous chondrocyte implantation (ACI) in people with symptomatic articular cartilage defects of the knee

Type

Technology appraisal guidance

Published

04 October 2017

Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in adults and children aged 2 months and over.

Type

Technology appraisal guidance

Published

16 December 2021

Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms in myelofibrosis in adults

Type

Technology appraisal guidance

Published

16 December 2021

Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults

Type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults

Type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia (AML) in adults

Type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults

Type

Technology appraisal guidance

Published

18 April 2018